Transcutaneous electrical nerve stimulation (TENS) is a treatment for pain that involves placement of electrical stimulation through the skin for pain relief. Previous work from our laboratory shows that repeated application of TENS produces analgesic tolerance by the fourth day and a concomitant cross-tolerance at spinal opioid receptors. Prior pharmacological studies show that blockade of cholecystokinin (CCK) receptors systemically and spinally prevents the development of analgesic tolerance to repeated doses of opioid agonists. We therefore hypothesized that systemic and intrathecal blockade of CCK receptors would prevent the development of analgesic tolerance to TENS, and cross-tolerance at spinal opioid receptors. In animals with knee joint inflammation (3% kaolin/carrageenan), high (100 Hz) or low frequency (4 Hz) TENS was applied daily and the mechanical withdrawal thresholds of the muscle and paw were examined. We tested thresholds before and after inflammation, and before and after TENS. Animals treated systemically, prior to TENS, with the CCK antagonist, proglumide, did not develop tolerance to repeated application of TENS on the fourth day. Spinal blockade of CCK-A or CCK-B receptors blocked the development of tolerance to high and low frequency TENS, respectively. In the same animals we show that spinal blockade of CCK-A receptors prevents cross-tolerance at spinal delta-opioid receptors that normally occurs with high frequency TENS; and blockade of CCK-B receptors prevents cross-tolerance at spinal mu-opioid receptors that normally occurs with low frequency TENS. Thus, we conclude that blockade of CCK receptors prevents the development of analgesic tolerance to repeated application of TENS in a frequency-dependent manner.
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Introduction
Transcutaneous electrical nerve stimulation (TENS) is the application of surface electrodes applied to the skin for pain relief [2] . Numerous clinical studies attempted to determine the effectiveness of TENS treatment for people with a variety of pain conditions. Systematic reviews and meta-analysis show that TENS is effective for osteoarthritis, rheumatoid arthritis, postoperative pain, and chronic musculoskeletal pain [7, 43, 44] . Early literature supports a role for opioids in TENS. Specifically, in human subjects systemic blockade of opioid receptors with naloxone prevents low, but not high, frequency TENS analgesia [47] . In animals, higher concentrations of systemic naloxone also prevent the effects of high frequency TENS analgesia [24, 64] . In parallel, opioid peptides are released in the cerebrospinal fluid and plasma in humans [22, 30, 46] in response to either low or high frequency TENS in a frequency-dependent manner. Previous studies from our laboratory extend those studies by showing the ability of opioid receptor antagonists administered directly to the rostroventromedial medulla (RVM) or the spinal cord prevents the anti-hyperalgesic effects of both high and low frequency TENS [1, 31] . Furthermore, repeated daily application of high or low frequency TENS produces tolerance at spinal delta-and muopioid receptors, respectively [8] . Clinically, development of opioid tolerance is an important and limiting factor to long-term opioid treatment. Since TENS uses opioid receptors and its repeated application produces analgesic tolerance it follows that chronic use of TENS in the clinical setting can be limited as well.
Cholecystokinin (CCK), a neuropeptide widely distributed in the mammalian nervous system [4], reverses analgesic effects of opioids, and co-administration of CCK antagonist and morphine prevents the development of opioid tolerance [33] . Similarly, CCK agonists block the analgesic effect of electroacupuncture and CCK receptor antagonists potentiate analgesic effects of electroacupuncture [11, 37] . Electroacupuncture also increases CCK release in spinal cord perfusate and this release is frequency-dependent with higher frequencies demonstrating greater release than lower 
